<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on April 3, 2026 at 2:09 pm by All in One SEO v4.8.7.2 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://visikol.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Visikol</title>
		<link><![CDATA[https://visikol.com]]></link>
		<description><![CDATA[Advanced Drug Discovery and Bioimaging Services]]></description>
		<lastBuildDate><![CDATA[Wed, 29 May 2024 11:42:41 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://visikol.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://visikol.com/blog/2024/05/29/maximizing-the-potential-of-in-vitro-immuno-oncology-models-with-high-content-imaging/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2024/05/29/maximizing-the-potential-of-in-vitro-immuno-oncology-models-with-high-content-imaging/]]></link>
			<title>Maximizing the Potential of In Vitro Immuno-Oncology Models with High Content Imaging</title>
			<pubDate><![CDATA[Wed, 29 May 2024 11:42:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2024/08/28/why-3d-cell-culture-matters/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2024/08/28/why-3d-cell-culture-matters/]]></link>
			<title>Why 3D Cell Culture Matters</title>
			<pubDate><![CDATA[Wed, 28 Aug 2024 15:33:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/about-us/careers/]]></guid>
			<link><![CDATA[https://visikol.com/about-us/careers/]]></link>
			<title>Careers</title>
			<pubDate><![CDATA[Wed, 27 Aug 2025 17:37:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/hurel-micro-livers/publications/]]></guid>
			<link><![CDATA[https://visikol.com/hurel-micro-livers/publications/]]></link>
			<title>HUREL® Publications</title>
			<pubDate><![CDATA[Wed, 26 Jun 2024 17:05:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/confocal-microscopy-for-3d-tissue-imaging/]]></guid>
			<link><![CDATA[https://visikol.com/confocal-microscopy-for-3d-tissue-imaging/]]></link>
			<title>Confocal Microscopy for 3D Tissue Imaging</title>
			<pubDate><![CDATA[Wed, 21 Jan 2026 13:12:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2024/11/20/how-our-in-vitro-immuno-oncology-immune-cell-infiltration-assay-can-accelerate-drug-discovery/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2024/11/20/how-our-in-vitro-immuno-oncology-immune-cell-infiltration-assay-can-accelerate-drug-discovery/]]></link>
			<title>How Our In Vitro Immuno-Oncology Immune Cell Infiltration Assay Can Accelerate Drug Discovery</title>
			<pubDate><![CDATA[Wed, 20 Nov 2024 15:08:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/]]></guid>
			<link><![CDATA[https://visikol.com/]]></link>
			<title>Visikol &#8211; Contract Research Services &#8211; Home</title>
			<pubDate><![CDATA[Wed, 08 Oct 2025 18:48:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/services/in-vitro-services/]]></guid>
			<link><![CDATA[https://visikol.com/services/in-vitro-services/]]></link>
			<title>In Vitro Services</title>
			<pubDate><![CDATA[Wed, 07 May 2025 17:42:37 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2025/02/05/in-vitro-methods-lead-the-way-in-antibody-pharmacokinetics/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2025/02/05/in-vitro-methods-lead-the-way-in-antibody-pharmacokinetics/]]></link>
			<title>In Vitro Methods Lead the Way In Antibody Pharmacokinetics</title>
			<pubDate><![CDATA[Wed, 05 Feb 2025 14:54:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/services/in-vitro/]]></guid>
			<link><![CDATA[https://visikol.com/services/in-vitro/]]></link>
			<title>3D Cell Culture Assay Services</title>
			<pubDate><![CDATA[Wed, 04 Sep 2024 13:26:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2025/06/03/hurel-services-products/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2025/06/03/hurel-services-products/]]></link>
			<title>HUREL Micro Livers Services and Products</title>
			<pubDate><![CDATA[Wed, 04 Jun 2025 14:15:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/product/ferret-brain-slicer/]]></guid>
			<link><![CDATA[https://visikol.com/product/ferret-brain-slicer/]]></link>
			<title>Ferret Brain Slicer</title>
			<pubDate><![CDATA[Tue, 28 Oct 2025 19:01:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2024/05/21/a-closer-look-at-visikols-liver-fibrosis-assay/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2024/05/21/a-closer-look-at-visikols-liver-fibrosis-assay/]]></link>
			<title>A Closer Look at Visikol&#8217;s Liver Fibrosis Assay</title>
			<pubDate><![CDATA[Tue, 21 May 2024 15:43:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2024/06/18/the-advantages-of-highly-multiplexed-ihc-services/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2024/06/18/the-advantages-of-highly-multiplexed-ihc-services/]]></link>
			<title>The Advantages of Highly Multiplexed IHC Services</title>
			<pubDate><![CDATA[Tue, 18 Jun 2024 13:42:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/about-us/]]></guid>
			<link><![CDATA[https://visikol.com/about-us/]]></link>
			<title>About</title>
			<pubDate><![CDATA[Tue, 15 Jul 2025 15:59:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2025/07/08/bridging-traditional-histology-with-next-generation-imaging/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2025/07/08/bridging-traditional-histology-with-next-generation-imaging/]]></link>
			<title>Bridging Traditional Histology with Next-Generation Imaging</title>
			<pubDate><![CDATA[Tue, 08 Jul 2025 20:05:43 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/services/digipath/validated-antibodies-2/]]></guid>
			<link><![CDATA[https://visikol.com/services/digipath/validated-antibodies-2/]]></link>
			<title>Validated Antibodies</title>
			<pubDate><![CDATA[Tue, 02 Apr 2024 18:36:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/services/digipath/multiplex-ihc/multiplex-panels/]]></guid>
			<link><![CDATA[https://visikol.com/services/digipath/multiplex-ihc/multiplex-panels/]]></link>
			<title>Multiplex Panels</title>
			<pubDate><![CDATA[Tue, 02 Apr 2024 17:44:35 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/plantbioredirect/]]></guid>
			<link><![CDATA[https://visikol.com/plantbioredirect/]]></link>
			<title>Unfortunately, Plant Bio Is No Longer Being Produced</title>
			<pubDate><![CDATA[Thu, 24 Oct 2024 16:34:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/products/]]></guid>
			<link><![CDATA[https://visikol.com/products/]]></link>
			<title>Products</title>
			<pubDate><![CDATA[Thu, 24 Jul 2025 12:45:21 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/product/visikol-for-plant-biology/]]></guid>
			<link><![CDATA[https://visikol.com/product/visikol-for-plant-biology/]]></link>
			<title>Visikol® for Plant Biology™</title>
			<pubDate><![CDATA[Thu, 24 Jul 2025 12:37:09 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/msds-coa/]]></guid>
			<link><![CDATA[https://visikol.com/msds-coa/]]></link>
			<title>MSDS/CoA</title>
			<pubDate><![CDATA[Thu, 15 Jan 2026 14:21:43 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2018/11/29/blog-post-loading-and-measurement-of-volumes-in-3d-confocal-image-stacks-with-imagej/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2018/11/29/blog-post-loading-and-measurement-of-volumes-in-3d-confocal-image-stacks-with-imagej/]]></link>
			<title>Blog Post: Loading and Measurement of Volumes in 3D Confocal Image Stacks with ImageJ</title>
			<pubDate><![CDATA[Thu, 11 Jul 2024 12:47:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/services/in-vitro/high-content-screening/]]></guid>
			<link><![CDATA[https://visikol.com/services/in-vitro/high-content-screening/]]></link>
			<title>High Content Screening</title>
			<pubDate><![CDATA[Thu, 11 Jul 2024 12:46:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2018/11/29/causes-for-autofluorescence-and-techniques-to-address-it-for-fluorescent-tissue-imaging/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2018/11/29/causes-for-autofluorescence-and-techniques-to-address-it-for-fluorescent-tissue-imaging/]]></link>
			<title>Causes for Autofluorescence and Techniques to Address it for Fluorescent Tissue Imaging</title>
			<pubDate><![CDATA[Thu, 11 Jul 2024 12:46:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2018/11/29/blog-post-the-case-for-3d-cell-culture-models/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2018/11/29/blog-post-the-case-for-3d-cell-culture-models/]]></link>
			<title>Blog Post: The Case for 3D Cell Culture Models</title>
			<pubDate><![CDATA[Thu, 11 Jul 2024 12:40:29 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/areas/nafld-nash-and-liver-disease/]]></guid>
			<link><![CDATA[https://visikol.com/areas/nafld-nash-and-liver-disease/]]></link>
			<title>NAFLD, NASH, and Liver Disease</title>
			<pubDate><![CDATA[Thu, 06 Jun 2024 19:38:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/hurel-overview/]]></guid>
			<link><![CDATA[https://visikol.com/hurel-overview/]]></link>
			<title>HUREL® Overview</title>
			<pubDate><![CDATA[Thu, 05 Sep 2024 17:37:22 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/services/tissue/applications/]]></guid>
			<link><![CDATA[https://visikol.com/services/tissue/applications/]]></link>
			<title>Example Applications of Tissue Imaging</title>
			<pubDate><![CDATA[Thu, 05 Sep 2024 16:41:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/hurel-micro-livers/hurel-micro-livers-2/]]></guid>
			<link><![CDATA[https://visikol.com/hurel-micro-livers/hurel-micro-livers-2/]]></link>
			<title>HUREL® Micro Livers</title>
			<pubDate><![CDATA[Sun, 14 Dec 2025 17:03:28 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2024/09/30/accelerating-drug-discovery-with-in-vitro-antibody-pharmacokinetics-assay/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2024/09/30/accelerating-drug-discovery-with-in-vitro-antibody-pharmacokinetics-assay/]]></link>
			<title>Accelerating Drug Discovery with In Vitro Antibody Pharmacokinetics Assay</title>
			<pubDate><![CDATA[Mon, 30 Sep 2024 19:38:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2024/07/29/overcoming-the-challenges-of-antibody-drug-distribution/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2024/07/29/overcoming-the-challenges-of-antibody-drug-distribution/]]></link>
			<title>Overcoming the Challenges of Antibody Drug Distribution</title>
			<pubDate><![CDATA[Mon, 29 Jul 2024 19:20:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2024/10/28/accelerating-drug-discovery-with-advanced-in-vitro-models/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2024/10/28/accelerating-drug-discovery-with-advanced-in-vitro-models/]]></link>
			<title>Accelerating Drug Discovery with Advanced In Vitro Models</title>
			<pubDate><![CDATA[Mon, 28 Oct 2024 16:50:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/resources/blogs/]]></guid>
			<link><![CDATA[https://visikol.com/resources/blogs/]]></link>
			<title>Blog Posts</title>
			<pubDate><![CDATA[Mon, 28 Oct 2019 15:44:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2024/09/23/maximizing-the-potential-of-liver-fibrosis-assay/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2024/09/23/maximizing-the-potential-of-liver-fibrosis-assay/]]></link>
			<title>Maximizing the Potential of Liver Fibrosis Assay</title>
			<pubDate><![CDATA[Mon, 23 Sep 2024 12:32:31 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/hurel-micro-livers/services/]]></guid>
			<link><![CDATA[https://visikol.com/hurel-micro-livers/services/]]></link>
			<title>HUREL® Micro Liver Services</title>
			<pubDate><![CDATA[Mon, 22 Sep 2025 15:20:47 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/services/]]></guid>
			<link><![CDATA[https://visikol.com/services/]]></link>
			<title>Contract Research Services</title>
			<pubDate><![CDATA[Mon, 22 Sep 2025 12:51:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2024/07/22/unlocking-the-potential-of-high-content-screening-with-in-vitro-bbb-permeability-assessment/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2024/07/22/unlocking-the-potential-of-high-content-screening-with-in-vitro-bbb-permeability-assessment/]]></link>
			<title>Unlocking the Potential of High Content Screening with In Vitro BBB Permeability Assessment</title>
			<pubDate><![CDATA[Mon, 22 Jul 2024 14:12:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2024/08/19/the-power-of-hurel-micro-livers-in-predicting-drug-toxicity/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2024/08/19/the-power-of-hurel-micro-livers-in-predicting-drug-toxicity/]]></link>
			<title>The Power of HUREL® Micro Livers in Predicting Drug Toxicity</title>
			<pubDate><![CDATA[Mon, 19 Aug 2024 19:10:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2023/10/23/an-overview-of-hurel-products/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2023/10/23/an-overview-of-hurel-products/]]></link>
			<title>An Overview of HUREL Products</title>
			<pubDate><![CDATA[Mon, 13 Oct 2025 14:01:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2024/11/11/accelerating-drug-discovery-with-high-content-screening-using-hurel-micro-livers/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2024/11/11/accelerating-drug-discovery-with-high-content-screening-using-hurel-micro-livers/]]></link>
			<title>Accelerating Drug Discovery with High-Content Screening using HUREL® Micro Livers</title>
			<pubDate><![CDATA[Mon, 11 Nov 2024 19:21:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2024/09/09/unlocking-new-possibilities-in-drug-discovery-with-highly-multiplexed-ihc/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2024/09/09/unlocking-new-possibilities-in-drug-discovery-with-highly-multiplexed-ihc/]]></link>
			<title>Unlocking New Possibilities in Drug Discovery with Highly-Multiplexed IHC</title>
			<pubDate><![CDATA[Mon, 09 Sep 2024 13:49:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/services/in-vitro/blood-brain-barrier/]]></guid>
			<link><![CDATA[https://visikol.com/services/in-vitro/blood-brain-barrier/]]></link>
			<title>Blood Brain Barrier Permeability Assay</title>
			<pubDate><![CDATA[Mon, 08 Apr 2024 17:45:29 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2024/10/07/maximizing-drug-efficacy-with-in-vitro-blood-brain-barrier-permeability-assessment/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2024/10/07/maximizing-drug-efficacy-with-in-vitro-blood-brain-barrier-permeability-assessment/]]></link>
			<title>Maximizing Drug Efficacy with In Vitro Blood Brain Barrier Permeability Assessment</title>
			<pubDate><![CDATA[Mon, 07 Oct 2024 14:09:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2024/08/05/the-advantages-of-in-vitro-immuno-oncology-models-for-immunotherapy-development/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2024/08/05/the-advantages-of-in-vitro-immuno-oncology-models-for-immunotherapy-development/]]></link>
			<title>The Advantages of In Vitro Immuno-Oncology Models for Immunotherapy Development</title>
			<pubDate><![CDATA[Mon, 05 Aug 2024 20:17:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2024/07/01/breaking-down-liver-fibrosis-understanding-the-disease-and-the-role-of-in-vitro-models/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2024/07/01/breaking-down-liver-fibrosis-understanding-the-disease-and-the-role-of-in-vitro-models/]]></link>
			<title>Breaking Down Liver Fibrosis: Understanding the Disease and the Role of In Vitro Models</title>
			<pubDate><![CDATA[Mon, 01 Jul 2024 17:46:51 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/maps-and-directions/]]></guid>
			<link><![CDATA[https://visikol.com/maps-and-directions/]]></link>
			<title>Maps and Directions</title>
			<pubDate><![CDATA[Fri, 31 Jan 2025 16:08:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/get-started-today/]]></guid>
			<link><![CDATA[https://visikol.com/get-started-today/]]></link>
			<title>Contact Us</title>
			<pubDate><![CDATA[Fri, 08 Aug 2025 19:27:43 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blood-brain-barrier/visikols-blood-brain-barrier-model/]]></guid>
			<link><![CDATA[https://visikol.com/blood-brain-barrier/visikols-blood-brain-barrier-model/]]></link>
			<title>Visikol&#8217;s Blood Brain Barrier Model</title>
			<pubDate><![CDATA[Fri, 06 Sep 2024 12:44:09 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://visikol.com/blog/2025/08/01/multiplex-immunofluorescence-in-drug-discovery/]]></guid>
			<link><![CDATA[https://visikol.com/blog/2025/08/01/multiplex-immunofluorescence-in-drug-discovery/]]></link>
			<title>Multiplex Immunofluorescence in Drug Discovery</title>
			<pubDate><![CDATA[Fri, 01 Aug 2025 13:09:38 +0000]]></pubDate>
		</item>
				</channel>
</rss>
